Huang Hsiang-Po, Chien Yin-Hsiu, Huang Li-Min, Ni Yen-Hsuan, Chang Mei-Hwei, Ho Ming-Chih, Lee Po-Huang, Hwu Wuh-Liang
Department of Pediatrics, National Taiwan University Hospital and National Taiwan University College of Medicine, Taipei, Taiwan.
J Formos Med Assoc. 2005 Sep;104(9):623-9.
Liver transplantation could be a useful treatment for selected inborn errors of metabolism. This study evaluated the outcome and viral infections after liver transplantation in young children and infants with these diseases.
The outcome of liver transplantation and clinical characteristics of the following 4 patients were assessed: 1 infant with ornithine transcarbamylase deficiency (OTCD) who received liver transplant aged 3 years and 4 months; 1 infant with carbamyl phosphate synthetase I deficiency (CPSID) who received liver transplant at 14 months of age; and 2 infants with methylmalonic acidemia (MMA) who received liver transplant at 8 months and 11 months of age, respectively. All donors, except the 8-month-old infant with MMA, showed serologic evidence of previous cytomegalovirus (CMV) infection before transplantation. All 4 of these donors showed serologic evidence of previous infection of Epstein-Barr virus (EBV). None of the recipients had previous CMV infection. Both the infant with OTCD and the 8-month-old infant with MMA had previous EBV infection, while the other 2 patients did not. Preoperative hemodialysis was performed in both infants with MMA. Postoperative follow-up included metabolic stability, disability degree, and viral infections.
None of the patients developed severe metabolic decompensation after transplantation and all increased protein intake postoperatively. Symptomatic viral infections, however, were present in all patients postoperatively, including CMV infection in the infant with OTCD and the 11-month-old infant with MMA, reactivation of EBV infection in the infant with OTCD and the 8-month-old infant with MMA, and primary EBV infection in the infant with CPSID.
Liver transplantation was an effective treatment for all 4 of these patients with inborn errors of metabolism. The risk of symptomatic viral infections for these patients was high. This was likely associated with conditions including immunosuppression, young age, endemic nature of CMV and EBV infections, and lack of CMV prophylaxis.
肝移植对于特定的先天性代谢缺陷可能是一种有效的治疗方法。本研究评估了患有这些疾病的幼儿和婴儿肝移植后的结局及病毒感染情况。
评估了以下4例患者肝移植的结局及临床特征:1例3岁4个月接受肝移植的鸟氨酸转氨甲酰酶缺乏症(OTCD)婴儿;1例14个月接受肝移植的氨甲酰磷酸合成酶I缺乏症(CPSID)婴儿;2例分别在8个月和11个月接受肝移植的甲基丙二酸血症(MMA)婴儿。除1例8个月大的MMA婴儿外,所有供者在移植前均有既往巨细胞病毒(CMV)感染的血清学证据。所有4例供者均有既往EB病毒(EBV)感染的血清学证据。所有受者既往均无CMV感染。OTCD婴儿和8个月大的MMA婴儿既往均有EBV感染,而其他2例患者没有。2例MMA婴儿术前均进行了血液透析。术后随访包括代谢稳定性、残疾程度和病毒感染情况。
所有患者移植后均未发生严重代谢失代偿,术后均增加了蛋白质摄入量。然而,所有患者术后均出现有症状的病毒感染,包括OTCD婴儿和11个月大的MMA婴儿发生CMV感染,OTCD婴儿和8个月大的MMA婴儿EBV感染复发,CPSID婴儿发生原发性EBV感染。
肝移植对这4例先天性代谢缺陷患者均是有效的治疗方法。这些患者发生有症状病毒感染的风险较高。这可能与免疫抑制、年龄小、CMV和EBV感染的地方性特点以及缺乏CMV预防措施等情况有关。